ASH2018 注目テーマ Late-Breaking Abstracts Session #4

イブルチニブとリツキシマブの併用で
未治療若年CLLのPFSとOSを延長 Randomized Phase Ⅲ Study of Ibrutinib (PCI-32765)-Based Therapy vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)

Tait D. Shanafelt（Stanford University, Stanford, CA）